Grant: Engage Grants Program
Ryerson University
$25,000.00
Development of novel high sensitivity cellular assays to complement artificial-intelligence-based rational design of small molecule protein inhibitors
EF 2018-19
Résumé
The development of specific small molecules that can modify or inhibit certain proteins represents critically important technology for many sectors, with applications ranging from drug compounds in the biomedical sector to small molecule inhibitors for use in industrial chemical manufacture. The identification of small molecule inhibitors or modifiers of protein function has to date been performed by resource-intensive processes involving screening of large libraries of chemical compounds in the laboratory. Cyclica Inc. has developed groundbreaking new artificial intelligence technology that allows rational drug design by the screening of interactions between small molecules and proteins in silico, at a fraction of the cost of laboratory screening assays. Cyclica Inc. now seeks a partnership with Dr. Costin Antonescu at Ryerson University and support in the form of this NSERC Engage grant to develop novel, highly sensitive laboratory cell-based assays to complement its existing molecular design pipeline. These new assays will allow assessment of the activity of the in silico designed small molecules on protein and cellular function in vitro. Moreover, these assays will allow assessment of the action of the small molecules on large numbers of individual cells in real time, as will be highly sensitive and represent cutting-edge, next generation transformative technology for Cyclica Inc. This represents a significant advancement and a large competitive for advantage Cyclica Inc., and as such an opportunity for this Canadian company to lead and to create high-level research and marketing positions.*
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
536770-2018
Name nom
Antonescu, Costin
Department département
Chemistry and Biology
Organization id
43
Institution établissement
Ryerson University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
1
Nb partie
1
Application title
Development of novel high sensitivity cellular assays to complement artificial-intelligence-based rational design of small molecule protein inhibitors
Keyword
NSERC
Application summary
The development of specific small molecules that can modify or inhibit certain proteins represents critically important technology for many sectors, with applications ranging from drug compounds in the biomedical sector to small molecule inhibitors for use in industrial chemical manufacture. The identification of small molecule inhibitors or modifiers of protein function has to date been performed by resource-intensive processes involving screening of large libraries of chemical compounds in the laboratory. Cyclica Inc. has developed groundbreaking new artificial intelligence technology that allows rational drug design by the screening of interactions between small molecules and proteins in silico, at a fraction of the cost of laboratory screening assays. Cyclica Inc. now seeks a partnership with Dr. Costin Antonescu at Ryerson University and support in the form of this NSERC Engage grant to develop novel, highly sensitive laboratory cell-based assays to complement its existing molecular design pipeline. These new assays will allow assessment of the activity of the in silico designed small molecules on protein and cellular function in vitro. Moreover, these assays will allow assessment of the action of the small molecules on large numbers of individual cells in real time, as will be highly sensitive and represent cutting-edge, next generation transformative technology for Cyclica Inc. This represents a significant advancement and a large competitive for advantage Cyclica Inc., and as such an opportunity for this Canadian company to lead and to create high-level research and marketing positions.*